A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Genomic rearrangements that give rise to oncogenic gene fusions can offer actionable targets for cancer therapy. Here we present a systematic analysis of oncogenic gene fusions among a clinically well-characterized, prospectively collected set of 278 primary colon cancers spanning diverse tumor stages and clinical outcomes. Gene fusions and somatic genetic variations were identified in fresh frozen clinical specimens by Illumina RNA-sequencing, the STAR fusion gene detection pipeline, and GATK RNA-seq variant calling. We considered gene fusions to be pathogenically relevant when recurrent, producing divergent gene expression (outlier analysis), or as functionally important (e.g., kinase fusions). Overall, 2.5% of all specimens were defined as harboring a relevant gene fusion (kinase fusions 1.8%). Novel configurations of BRAF, NTRK3, and RET gene fusions resulting from chromosomal translocations were identified. An R-spondin fusion was found in only one tumor (0.35%), much less than an earlier reported frequency of 10% in colorectal cancers. We also found a novel fusion involving USP9X-ERAS formed by chromothripsis and leading to high expression of ERAS, a constitutively active RAS protein normally expressed only in embryonic stem cells. This USP9X–ERAS fusion appeared highly oncogenic on the basis of its ability to activate AKT signaling. Oncogenic fusions were identified only in lymph node–negative tumors that lacked BRAF or KRAS mutations. In summary, we identified several novel oncogenic gene fusions in colorectal cancer that may drive malignant development and offer new targets for personalized therapy. Cancer Res; 77(14); 3814–22. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids
Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., & Sato, T. (2015) · Nature Medicine · doi:10.1038/nm.3802 · Cited by 1,135 · cited 1×
“These key primary drivers are sufficient for the transformation of primary colon stem cells into genomically instable adenocarcinomas (5,6).”
BackgroundSequential cancer mutations in cultured human intestinal stem cells
Drost, J., van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R. M., Offerhaus, G. J., Begthel, H., et al. (2015) · Nature · doi:10.1038/nature14415 · Cited by 1,067 · cited 2×
“We anticipate that incorporating in vitro platforms such as (tumor)organoids may facilitate testing of fusion genes for functional relevance, differences in oncogenic capacity and response to anti-tumor drugs (5).”
BackgroundRecurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 1×
“Although BRAF fusions are relatively rare, they may be highly relevant drug targets for the individual patient, similar as mutations in BRAF (40-42).”
BackgroundThe landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450 · cited 3×
“Finally, a variety of kinase fusions have been observed in CRC, such as those involving BRAF or receptor tyrosine kinases (10,11,15,16).”
BackgroundCurrent targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Cited by
RNA sequencing: new technologies and applications in cancer research
Hong, M., Tao, S., Zhang, L., Diao, L.-T., Huang, X., Huang, S., Xie, S.-J., Xiao, Z.-D., & Zhang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01005-x · Cited by 596
Testa, U., Pelosi, E., & Castelli, G. (2018) · Medical Sciences · doi:10.3390/medsci6020031 · Cited by 374
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Amatu, A., Sartore-Bianchi, A., Bencardino, K., Pizzutilo, E. G., Tosi, F., & Siena, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz383 · Cited by 309
Molecular characterization of colorectal cancer related peritoneal metastatic disease
Lenos, K. J., Bach, S., Ferreira Moreno, L., ten Hoorn, S., Sluiter, N. R., Bootsma, S., Vieira Braga, F. A., Nijman, L. E., van den Bosch, T., Miedema, D. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32198-z · Cited by 125
Self-citation
Metadata
- Authors
- Kloosterman, W. P., Coebergh van den Braak, R. R. J., Pieterse, M., van Roosmalen, M. J., Sieuwerts, A. M., Stangl, C., Brunekreef, R., Lalmahomed, Z. S., Ooft, S., van Galen, A., Smid, M., Lefebvre, A., Zwartkruis, F., Martens, J. W. M., Foekens, J. A., Biermann, K., Koudijs, M. J., Ijzermans, J. N. M., & Voest, E. E.
- Venue
- Cancer Research
- Published
- 2017-07-13
- Volume
- 77
- Issue
- 14
- Pages
- 3814-3822
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2616119389
- Cited by
- 94
- References
- 10
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-3563
- The paper
- Kloosterman, W. P., Coebergh van den Braak, R. R. J., Pieterse, M., van Roosmalen, M. J., Sieuwerts, A. M., Stangl, C., Brunekreef, R., Lalmahomed, Z. S., Ooft, S., van Galen, A., Smid, M., Lefebvre, A., Zwartkruis, F., Martens, J. W. M., Foekens, J. A., Biermann, K., Koudijs, M. J., Ijzermans, J. N. M., & Voest, E. E. (2017). A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-3563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.